Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 116.57% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 63.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.40% |
| Dec 31, 2025 | 284.50% |
| Sep 30, 2025 | 128.47% |
| Jun 30, 2025 | 431.75% |
| Mar 31, 2025 | -16.42% |
| Dec 31, 2024 | -192.80% |
| Sep 30, 2024 | -41.88% |
| Jun 30, 2024 | -5.65% |
| Mar 31, 2024 | 46.22% |
| Dec 31, 2023 | -236.18% |
| Sep 30, 2023 | -100.97% |
| Jun 30, 2023 | -185.12% |
| Mar 31, 2023 | -239.10% |
| Dec 31, 2022 | -84.90% |
| Sep 30, 2022 | 4,400.00% |
| Jun 30, 2022 | 47.61% |
| Mar 31, 2022 | 128.92% |
| Dec 31, 2021 | 134.26% |
| Sep 30, 2021 | 127.98% |
| Jun 30, 2021 | 119.80% |